Effectiveness of Saline Nasal Irrigation in the Treatment of Rhinosinusitis and Allergic Rhinitis in Pediatric Patients: A Systematic Review. [PDF]
Salgado M +9 more
europepmc +1 more source
ABSTRACT Allergen immunotherapy (AIT) has been acknowledged as the only disease‐modifying treatment for respiratory diseases since its introduction in 1911. Although the efficacy and safety have convincingly been established in numerous randomized clinical trials (RCTs), the AIT study results may vary substantially.
Roy Gerth van Wijk +10 more
wiley +1 more source
Human IgE Antibodies Recognize the Vicilin and Alpha‐Hairpinin Domains of Peanut Allergen Ara h 1
The ɑ‐hairpinin of Ara h 1 contains a dominant epitope that is both frequently recognized and blocks a majority of the IgE against this domain. Including this region in tests may improve diagnosis of peanut allergy. The trimeric structure of the vicilin region explains the ability of Ara h 1 to induce anaphylaxis with a single antibody.
Taylor M. Cosey +14 more
wiley +1 more source
Correction: Study on the pathogenesis of PLXNB1 gene in olfactory dysfunction of allergic rhinitis. [PDF]
Chen X, Zhao L, Luo W.
europepmc +1 more source
Asthma Remission From Childhood to Young Adulthood–A Population‐Based Cohort Study
Among 257 participants with asthma at age 8 years, 39% achieved symptom‐based remission by age 24, 29% achieved clinical remission, and 18% achieved complete remission. Male sex increased the likelihood of symptom‐based remission, while food sensitization and overweight/obesity decreased the likelihood.
Lina Broström +6 more
wiley +1 more source
Efficacy of Histaglobulin in Allergic Diseases: A Systematic Review and Meta-Analysis with Implications for Allergic Rhinitis. [PDF]
Oh J, Choi JH.
europepmc +1 more source
TL1A morphological shifts and inflammatory heterogeneity in rhinosinusitis and allergic rhinitis: a hypothesis-driven review. [PDF]
Pei T, Li X.
europepmc +1 more source
Pre‐Seasonal Treatment With Recombinant Carrier‐Based Birch Vaccine Improves Birch Pollen Allergy
We conducted a two stage SCIT trial with GNR‐127 containing a recombinant fusion protein consisting of Bet v 1 and Mal d 1‐derived peptides fused to PreS from HBV. Stage 1 identified two safe maximum tolerated doses (40 μg and 80 μg). In the following Stage 2, five preseasonal injections were well tolerated, induced dose‐dependent allergen‐specific IgG,
Musa R. Khaitov +43 more
wiley +1 more source

